Pre Market
|
||||
|
|
|
|
Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-3.14/-1.64
|
Enterprise Value
135.27M
|
Balance Sheet |
Book Value Per Share
4.11
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
0
|
Operating Revenue Per Share
--
|
Industry Comparison
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|

Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer(Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. |